Gonzales v. Raich
A 2005 Supreme Court ruling confirming federal authority over state medical cannabis programs.
This case settled the constitutional question: federal law beats state law on cannabis, full stop. But it didn't ban Prop 215 or force states to arrest patients. The real compromise—legal weed under state law, tolerated by federal prosecutorial discretion—exists because Raich closed the constitutional door. That's why legalization happened through politics, not courts.
Background: Prop 215 and two California patients
In 1996, California voters passed Proposition 215, the Compassionate Use Act, making California the first state to legalize medical cannabis under state law. The federal Controlled Substances Act (CSA), passed in 1970, still classified cannabis as Schedule I — no accepted medical use, high abuse potential.
Angel Raich and Diane Monson were two California residents using cannabis on their physicians' recommendations. Raich, of Oakland, had an inoperable brain tumor and a list of other serious conditions; her physician stated that cannabis was necessary to keep her alive and manage pain. Monson, of Oroville, used cannabis for chronic back pain and cultivated six plants at home for personal use. On August 15, 2002, federal DEA agents and county sheriffs raided Monson's home. The local officers concluded she was in compliance with state law; the DEA seized and destroyed her plants anyway.
Raich and Monson sued in federal court to block enforcement of the CSA against them. Their legal theory was that the CSA, as applied to their conduct—intrastate, noncommercial, medically necessary cannabis cultivation under state law—exceeded Congress's authority under the Commerce Clause of the U.S. Constitution.
Path to the Supreme Court
The case was originally filed as Raich v. Ashcroft in the U.S. District Court for the Northern District of California in 2002. The district court denied the plaintiffs' request for a preliminary injunction. On appeal in December 2003, the U.S. Court of Appeals for the Ninth Circuit reversed, holding that Raich and Monson had shown a strong likelihood of success on the merits [1]. The panel ruled that their conduct constituted 'a separate and distinct class of activities' from the interstate drug market Congress was regulating.
The Ninth Circuit relied on two recent Supreme Court decisions from the Rehnquist era: United States v. Lopez (1995) and United States v. Morrison (2000), both of which had struck down federal statutes as exceeding Commerce Clause authority [2]. These cases suggested a real constitutional limit on federal reach into purely local, noneconomic activity. Legal commentators believed Lopez and Morrison might signal a turning point.
The United States petitioned the Supreme Court for certiorari. By the time the Court heard oral argument on November 29, 2004, John Ashcroft had left office and Alberto Gonzales had become Attorney General, prompting a name change to Gonzales v. Raich.
The Supreme Court decision
On June 6, 2005, the Supreme Court ruled 6–3 in favor of the government. Justice John Paul Stevens wrote the majority opinion, joined by Justices Anthony Kennedy, David Souter, Ruth Bader Ginsburg, and Stephen Breyer. Justice Scalia concurred separately. Strong evidence
The majority rested its reasoning on Wickard v. Filburn (1942), the New Deal–era precedent upholding federal wheat quotas against a farmer growing wheat for his own consumption [3]. Even purely local, noncommercial conduct, when aggregated with similar conduct nationwide, could substantially affect interstate commerce and thus fall within Congress's regulatory reach.
Stevens's opinion held that homegrown medical cannabis, in the aggregate, could affect the interstate illicit drug market. Patients might divert homegrown cannabis to the black market, or homegrown supply might reduce demand for illicit cannabis purchased across state lines. Under the CSA's comprehensive regulatory scheme, Congress could rationally conclude that carve-outs for medical cannabis would undermine the entire statutory regime.
Justice Scalia's concurrence grounded his vote differently, relying on the Necessary and Proper Clause rather than an expansive Commerce Clause theory.
Justice Sandra Day O'Connor dissented, joined by Chief Justice William H. Rehnquist and Justice Clarence Thomas. She warned that the majority had effectively gutted Lopez and Morrison, leaving Congress with essentially unlimited reach into purely local, noneconomic conduct. Justice Thomas filed a separate, more forceful dissent, arguing: 'If Congress can regulate this under the Commerce Clause, then it can regulate virtually anything — and the Federal Government is no longer one of limited and enumerated powers'. Thomas voted with the plaintiffs on federalism grounds, not in opposition to medical cannabis.
Aftermath for the plaintiffs
After the Supreme Court's decision, the case was remanded to the Ninth Circuit. Raich pursued alternative constitutional theories: that the Fifth Amendment's substantive due process guarantee, combined with a common-law medical necessity defense, should shield her from prosecution. In March 2007, the Ninth Circuit rejected both arguments in Raich v. Gonzales [4].
Despite the unfavorable ruling, neither Raich nor Monson was ever criminally prosecuted by federal authorities following the litigation. Raich continued to use cannabis publicly and became an advocate for medical cannabis rights. Monson likewise avoided federal charges. The case did not result in criminal prosecution of the plaintiffs.
What Raich established
The decision settled several legal points:
- Federal law preempts state law on cannabis. Strong evidence The CSA's Schedule I classification applies within states that have legalized medical or adult-use cannabis. State law does not nullify federal prohibition.
- Federal agents retain enforcement authority. Strong evidence The DEA and other federal law enforcement may raid, seize assets, and prosecute individuals and businesses fully compliant with state cannabis law.
- Broad Commerce Clause deference applies to the CSA. Strong evidence The Supreme Court adopted an expansive reading of federal commerce power in the drug context, making Commerce Clause challenges to federal drug prohibition extraordinarily difficult to mount successfully.
These rulings align with modern Commerce Clause jurisprudence: since the New Deal, the Court has rarely struck down a federal statute as exceeding commerce power, and Lopez and Morrison remain narrow exceptions. Raich confirmed that drug regulation falls well within federal reach.
What Raich did not do
Common misreadings persist. What Raich explicitly did not do:
- It did not strike down or invalidate Proposition 215 or any state medical marijuana law. Strong evidence Prop 215 remained in force as California state law after Raich and continues to do so. State legalization statutes stand; they simply do not override federal law.
- It did not require states to enforce federal cannabis law. Strong evidence Under the anti-commandeering doctrine established in Printz v. United States (1997), the federal government cannot compel state officers to enforce federal statutes. Consequently, states can and do decline to prosecute cannabis offenses that comply with state law, which every legalization state now does [5].
- It did not settle the medical necessity defense in federal court. That issue was resolved separately in United States v. Oakland Cannabis Buyers' Cooperative (2001), a different case in which the Supreme Court held that the medical necessity defense is unavailable as a matter of federal drug law [6].
The practical outcome—legal cannabis under state law, illegal under federal law, tolerated through prosecutorial discretion and congressional funding riders—emerged because Raich closed the constitutional avenue, leaving only political remedies.
Legacy and political compromise
Since Raich, the United States has lived under a federalism compromise that the decision itself did not mandate but made inevitable. Because the Supreme Court confirmed that the CSA constitutionally applies nationwide, legalization could not occur through constitutional litigation. It occurred instead through state ballot initiatives and political negotiation at the federal level.
In 2013, the Department of Justice issued the Cole Memorandum, a prosecutorial guidance document stating that federal cannabis prosecution would not be a priority for state-compliant medical programs No data. More durably, beginning in 2014, Congress began attaching annual riders to appropriations bills—most notably the Rohrabacher–Farr amendment—prohibiting the Department of Justice from spending funds to prosecute individuals and businesses operating in compliance with state medical cannabis law. The Ninth Circuit affirmed this spending restriction in United States v. McIntosh (2016), holding that the rider created a binding bar on prosecution [7].
These constraints are statutory and annual, not constitutional. Congress renews them each year. A change in congressional majorities or administration could reverse them without amending the Constitution. That fragility reflects Raich's core holding: the Constitution, as interpreted by the Court, places no structural limit on federal cannabis prohibition.
Common myths about Raich
Myth: 'Raich made medical marijuana illegal.' Disputed The decision did not. It held that federal law applies and preempts conflicting state law. Prop 215 remained in force; state medical programs expanded after Raich.
Myth: 'Justice Thomas voted against medical marijuana patients.' Disputed Thomas dissented for Raich and Monson, on federalism grounds. He wrote one of the strongest constitutional defenses of the plaintiffs' position, arguing that the majority violated principles of enumerated federal powers.
Myth: 'Raich means the DEA can arrest any state-legal dispensary owner any time, with no legal constraint.' Legally, the constitutional authority exists; Raich permits it. In practice, since 2014, the Rohrabacher–Farr appropriations rider has prohibited DOJ from spending funds to prosecute state-compliant medical operators—a limit the Ninth Circuit enforced in McIntosh (2016) [7]. That is a spending restriction, not a constitutional shield, and Congress votes to renew it annually.
Sources
- Government Raich v. Ashcroft, 352 F.3d 1222 (9th Cir. 2003).
- Government United States v. Lopez, 514 U.S. 549 (1995); United States v. Morrison, 529 U.S. 598 (2000).
- Government Wickard v. Filburn, 317 U.S. 111 (1942).
- Government Raich v. Gonzales, 500 F.3d 850 (9th Cir. 2007) (on remand, rejecting substantive due process and medical necessity defenses).
- Government Printz v. United States, 521 U.S. 898 (1997) (anti-commandeering doctrine).
- Government United States v. Oakland Cannabis Buyers' Cooperative, 532 U.S. 483 (2001).
- Government United States v. McIntosh, 833 F.3d 1163 (9th Cir. 2016) (interpreting the Rohrabacher–Farr appropriations rider to bar DOJ prosecution of state-compliant medical cannabis defendants).
- Reported Greenhouse, Linda. 'Justices Say U.S. May Prohibit the Use of Medical Marijuana.' The New York Times, June 7, 2005.
How this page was made
Generation history
Drafted with AI assistance and checked by a separate automated fact-check pass. Not every article has been read by a person. See how articles are made.
Related
- Cannabis Buyers' Clubs of the 1990s — The informal dispensary networks that transformed cannabis from crime to state-legal medic...
- UN Drug Treaties and Cannabis — Three UN treaties control cannabis globally; legalization exists despite treaty language f...